scholarly journals Classification, diagnosis, and treatment of idiopathic short stature

2009 ◽  
Vol 55 (4) ◽  
pp. 36-44
Author(s):  
A N Shandin ◽  
V A Peterkova

Idiopathic short stature is the low stature in which all possible causes are excluded. The diagnosis and treatment of idiopathic short stature are the subject of constant controversy and discussion. With the expansion of indications for growth hormone therapy for conditions unaccompanied by growth hormone deficiency, there has been recently a challenge as to its use in idiopathic short stature. To date, there has been much worldwide evidence for the efficiency and safety of growth hormone therapy in children with idiopathic short stature. In 2008, the International consensus on the diagnosis and management of idiopathic short stature, prepared through the joint collaboration of three research societies: the Growth Hormone Society, the Lowson Wilkins Society of Pediatric Endocrinology (USA), and the European Society of Pediatric Endocrinology. The main points of this document have formed the basis for this paper.

2018 ◽  
Vol 44 (1-2) ◽  
pp. 16-26 ◽  
Author(s):  
Michal Yackobovitch-Gavan ◽  
Galia Gat-Yablonski ◽  
Biana Shtaif ◽  
Shir Hadani ◽  
Shiran Abargil ◽  
...  

2007 ◽  
Vol 68 (2) ◽  
pp. 53-62 ◽  
Author(s):  
Michael B. Ranke ◽  
Anders Lindberg ◽  
David A. Price ◽  
Feyza Darendeliler ◽  
Kerstin Albertsson-Wikland ◽  
...  

1997 ◽  
Vol 130 (2) ◽  
pp. 205-209 ◽  
Author(s):  
Masahiko Kawai ◽  
Toru Momoi ◽  
Tohru Yorifuji ◽  
Chutaro Yamanaka ◽  
Hiroshi Sasaki ◽  
...  

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Zeyad El-Naghy ◽  
Nicholas Andrew Krasnow ◽  
James Haigney ◽  
Tara Patale ◽  
Liam McGuirk ◽  
...  

Abstract Background: The sequential follow-up of simple fluid-filled pituitary cysts (PC) has not been fully elucidated. In this study, we further report our follow up of PCs in a cohort of pediatric patients (PTs). Objective: To further analyze the sequential cyst volume (CV) change in short children. Patients and Methods: A pediatric endocrinology and neuroradiology center was queried for the presence of PCs. PTs who underwent multiple high resolution post-contrast MRIs (1mm slices) were subjects of this study. PTs with additional MRI abnormalities were excluded. Pituitary volumes (PV) and CVs were measured using the ellipsoid formula (LxWxH/2). The percentage of the gland occupied by the cyst (POGO) was measured and calculated. A cyst with a POGO ≤15% was defined as a small pituitary cyst (SPC), and a POGO >15% was defined as a large pituitary cyst (LPC). 34 PTs met inclusion criteria, all of whom were diagnosed with short stature (23 growth hormone deficient (GHD) PTs and 11 idiopathic short stature (ISS) PTs). All PTs were receiving GH during data collection. Results: The mean (MN) and median (MD) ages for these subjects were 10.7 yrs ±3.5 and 11.1 yrs, respectively (RSP). Of the 34 PTs, 24 PTs’ (71%) initial MRI demonstrated a SPC and 10 PTs’ (29%) initial MRI demonstrated a LPC. The MN and MD times between first and second MRIs were 1.23 yrs and 0.83 yrs RSP, with a range (RG) of 0.14 to 4.08 yrs. The MN and MD ΔCV for all PTs was 23.33% ±179.17% and -25.94% RSP, with a RG of -100.00% to 763.94%. The MN and MD ΔPOGO by the cyst for all PTs was 48.59% ±313.26% and -36.84% RSP, with a RG of -100.00% to 1734.79%. The MN and MD ΔCV for PTs with a SPC was 10.68% ±2.65% and 11.09% RSP, with a RG of -100.00% to 763.94%. The MN and MD ΔPOGO by the cyst for PTs with a SPC was 78.33% ±369.96% and -31.34% RSP, with a RG of -100.00% to 1734.79%. The MN and MD ΔCV for PTs with a LPC was -24.60% ±51.89% and -26.57% RSP, with a RG of -88.57% to 91.38%. The MN and MD ΔPOGO by the cyst for PTs with a LPC was -22.79% ±44.90% and -40.46% RSP, with a RG of -80.95% to 47.11%. Statistical analysis showed no significant %ΔCV or %ΔPOGO when comparing male vs. female, SPC vs. LPC, GHD vs. ISS, or pre-pubertal vs. pubertal PTs. Analysis of ΔPOGO of the 24 SPC PTs demonstrated that 4 (17%) of them developed into LPCs. Analysis of the 10 LPC PTs showed that 6 (60%) of them shrunk into SPCs, one of which re-enlarged into a LPC, and another of which fluctuated between LPC and SPC over a period of 7.34 yrs and 9 sequential MRIs. None of the PTs experienced significant sequelae related to their PCs. Conclusion: CV can change greatly over time, however few sequelae should be expected. LPCs tend to demonstrate major changes in size and should be tracked for CV change. A minority of SPCs will develop into LPCs. Prediction of change in CV over time requires more sequential data. Change in CV did not appear to be influenced by GH therapy.


2019 ◽  
Vol 70 (2) ◽  
pp. 571-574
Author(s):  
Alin Demetrian ◽  
Smaranda Adelina Preda ◽  
Oana Mariana Cristea ◽  
Carmen Dragomirescu ◽  
Ionela Mihaela Vladu

Idiopathic short stature (ISS) deficiency reflects a major public health issue. In Romania the incidence is 1/3000 - 6000 births, with an increased prevalence in boys. ISS is the condition where the height of a subject is more than -2.5 DS below the height of the population for the population in which it is included, below the mean height for age and sex, but without any nutritional, systemic or chromosomal abnormalities. Significant for children with ISS is that weight is normal at birth and growth hormone levels are normal. This study shows the evolution of the height to normal values specific to the biological age, reaching the normal stature, according to auxological parameters, after growth hormone therapy.


Sign in / Sign up

Export Citation Format

Share Document